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Nanoparticles are small objects with diameter under one micrometer, typically around 100
nanometres. They have been widely studied as potential drug carriers due to their capability
to carry different drug molecules, while their surface may be modulated for better
bioavailability. For example, different targeting molecules such as peptides and antibodies
can be bound onto the surface of the particles to improve their cell and tissue specificity.
A major challenge in the use of nanoparticles in biomedicine is their fast removal from the
circulation due to the opsonisation caused by several plasma proteins which bind onto the
surface of the particles. These so called opsonins are then recognized by macrophages of the
reticuloendothelial system, leading to the elimination of the particles from the blood stream
before the carried drug molecule reaches its target tissue or organ. However, the circulation
time of the nanoparticles can be increased by altering the surface structure of the particles.
In other words, different surface chemistry can prevent opsonisation and the macrophage
uptake of the particles, therefore increasing their abilities as drug carriers.
Various polymers and polysaccharides have been used to shield nanoparticles. In this study,
three kinds of polysaccharides (chitosan, alginate and heparin) were used to compose layers
around mesoporous silicon nanoparticles in order to decrease the macrophage uptake of the
particles.  Also,  the  effect  of  cross  linking  of  the  shielding  layers  was  studied.  The
opsonisation rate and stability of the polysaccharide coated nanoparticles were tested in
vitro, by using gel electrophoresis and plasma tests. Furthermore, the nanoparticles were
radiolabeled with radioactive iodine, followed by in vivo –experiments in mice to study their
biodistribution.
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4LIST OF ABBREVIATIONS
AcOH Acetic acid
AEASP 3-(2-Aminoethylamino) propyldimethoxymethylsilane
Alg Alginate
Chi Chitosan
Cl Crosslinked
DIC N,N’-diisopropylcarbondiimide
EDC 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide
EDTA Ethylenediaminetetraacetic acid
FITC Fluorescein isothiocyanate
HCl Hydrochloric acid
Hepa Heparin
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HSA Human serum albumin
125I Iodine-125 –isotope
IgG Immunoglobulin G
Lbl Layer by layer
MES 2-(N-morpholino) ethanesulfonic acid
MPS Mononuclear phagocyte system
NaCl Sodium chloride
NHS N-hydroxysuccinimide
5NP Nanoparticle
O-PEG Oleyl-polyethylene glycol
PBS Phosphate buffered saline
PEG Polyethylene glycol
PET Positron emission topography
Phl Phloretic acid (3-(4-hydroxyphenyl) propionic acid)
PSi Porous silicon
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis
TCPSi-NH2 Thermally hydrocarbonized porous silicon amino particles
Tyr Tyrosine
UnTHCPSi Undecylenic acid treated thermally hydrocarbonized porous silicon
?-potential Zeta-potential
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9INTRODUCTION
1. Nanoparticles
Recently, nanotechnology has received increasing attention in drug design. The ability of
avoiding potentially harmful large doses of drugs together with considerably increased tissue
specificity has lead to development of small, injectable nanoparticles. These can be used to
carry drugs to specific locations of the body, for example tumors or sites of inflammations,
while maintaining a sustained release of the drug. Additionally, they can operate as drugs
themselves or as imaging agents.
  1.1 Characteristics
Nanoparticles (figure 1) are nanoscale objects with diameter under one micrometer. Their
size varies from a couple of nanometres up to one micrometer; larger particles are
considered microparticles. The typical size of the nanoparticles used in biomedicine has a
range  of  50  to  400  nm.  This  is  due  to  the  fact  that  the  size  affects  significantly  the
bioavailability and biodistribution of the particles and therefore their usefulness as drug
carriers. Diameter of few hundred nanometres has been shown to give the best results since
small particles are removed from the system via kidneys while large particles are susceptible
to macrophages. (Huang et al. 2011, He et al. 2011, Bimbo et al. 2010, Liu et al. 2009)
Hydrophilicity of the nanoparticles is another important factor that affects their
pharmacokinetics. The structure of the particles resembles often liposomes or micelles,
bearing hydrophilic surface and more hydrophobic core. Actually, the first nanoparticles
used as drug carriers were based on liposomes. Hydrophilic surface blocks opsonisation and
allows easier movement within the body while hydrophobic core is beneficial for drug
loading. (Lemarchand et al. 2004, Owens et al. 2006, Kovalainen et al. 2011, Farokhzad et al.
2009)
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Figure 1. The basic structure of nanoparticles drug carrier. Drug molecules are loaded into the
particles while targeting or shielding moieties are conjugated onto the surface.
Perhaps the most important factor in the pharmacokinetics of the nanoparticles is their
surface structure. In addition to hydrophilicity, the charge of the surface, functional groups
and surface area are all key factors to the bioavailability. Furthermore, drug loading
capability depends highly on these factors. As an example, the charge of the particle surface
can either increase or decrease their elimination rate from circulation; too high positive or
negative charge attracts opsonins, which are important factors in mononuclear phagocyte
system (MPS). (Lemarchand et al. 2004, Owens et al. 2006) The functional groups allow
further surface modification of the particles which is often crucial when designing effective
drug carriers. These will be discussed in details in chapter 4.
Other characteristics that have effect on the behaviour and usefulness of the nanoparticles
are their stability, shape and the material which the particles are composed of. The particles
have to be stable enough in the body conditions for efficient drug transportation. The shape
of the particles, spherical or rod-like, affects their biodistribution and loading capabilities. (Ya
et al. 2011, Kennedy et al. 2011) For example Huang et al. have shown that long rod-shaped
particles accumulate in spleen and have slower urinal excretion rate. (Huang et al. 2011)
  1.2 General types of nanoparticles
Nanoparticles can be composed of various materials with their own advantages and
disadvantages. Metal nanoparticles, mainly gold and silver ones, are one common type of
particles as they have useful tunable optical properties as well as large surface area.
Nanoparticle
Drug
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Furthermore, they are easily synthesized for example from organic template polymers or
around silica cores. Gold nanoparticles have received more attention even though particles
made of silver have antimicrobial properties. On the contrary, some studies have shown that
silver particles are cytotoxic, cause inflammatory responses and are therefore not
biocompatible. (Kennedy et al. 2011, Yuan et al. 2010, Chrastina et al. 2010)
Gold nanoparticles, nanorods, silica cores and biomolecule-conjugations have useful optical
characteristics. For example the bioavailability of the particles can be modified by light
beams for example to induce heat in photothermal adaptations. These properties of the gold
nanoparticles together with the possibility of further surface modifications allow versatile
medical applications including cancer treatment via hyperthermia, detection of DNA
mutations and various bioimaging techniques. (Fujita et al. 2012, Kennedy et al. 2011)
Another type of nanoparticles is those made of organic components such as proteins, lipids
and polymers. The advantages of these are high biocompatibility and –degradability as well
as non-toxicity, since usually they are composed of common system molecules such as
albumin. In addition, this offers biotargeting possibilities. For example Fan et al composed
insulin nanoparticles for polypeptide delivery. In another study of radioimaging, Ozgur et al
utilized nanoparticles made of albumin due to its biodegradability and tunable size. A
disadvantage of organic nanoparticles is that they are not as stable as metal or silicon
nanoparticles. (Ozgur et al. 2012, Pawar et al. 2012, Fan et al. 2006)
This Master’s thesis concentrates on nanoparticles with the structure based on porous
silicon  (PSi)  which  is  biodegradable  and  –compatible  material.  The  major  advantage  of
porous silicon particles is their excessive internal surface area and pore volume which allows
loading of larger amounts and variety of drugs compared to other types of nanoparticles. In
addition, PSi-particles are stable while their size and morphology can be tuned. Also, many
studies have shown that porous silicon increases not only the amount of loaded drug
molecules but also their solubility and release profiles. (Kovalainen et al. 2011, Rytkönen et
al. 2011, He et al. 2011, Bimbo et al. 2010)
Porous silicon nanoparticles can be produced in many ways. The most common procedure is
to use three-step pulsed electrochemical etching method from silicon wafers in corrosive
hydrogen fluoride, in which a low-porosity stable layer, high-porosity fragile layer and a high-
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porosity release layer, are produced during the etching process. Nanoparticles are then
produced by milling at the layered porous films. The pore diameter, pore volume and
particle size can be controlled with the etching parameters. The PSi-structure can be further
modified by for example thermal hydrocarbonization or oxidization, which conjugate
hydrocarbons or oxygen atoms to the surface of the PSi-particles. This stabilizes the silicon
structure and allows functionalizing of the surface with for instance undecylenic acid or
amine groups. (UnTHCPSi- and TCPSi-NH2 -nanoparticles). (Serda et al. 2011, Kovalainen et
al. 2011, Rytkönen et al. 2011)
Due to the appropriate characteristics described above porous silicon nanoparticles have
been utilized in many drug carrier experiments in which various drug molecules, peptides,
siRNA and anticancer chemotherapeutics have been loaded into PSi-particles and delivered
to their targets with promising results. (Serda et al. 2011, Kovalainen et al. 2011, Lee et al.
2010, Meng et al. 2010) Their biodistribution has also been studied for example by Bimbo et
al and Rytkönen et al. It seems that each type of PSi-particles tend to be removed from the
body via the complement system or urine depending on the administration route. This can
be considered as a minor drawback of the PSi-particles; they need further surface
modifications such as targeting agents and shielding moieties conjugated to the surface.
(Rytkönen et al. 2011, Bimbo et al. 2010)
2. Nanoparticles in pharmaceutical research
Nanoparticles have been utilized in countless different adaptations from corrosion
protection  to  soil  analysis.  Nowadays,  uses  in  pharmaceutical  research  are  of  growing
interest. In biomedicine nanoparticles are used as drug-carriers or in bioimaging studies,
there are numerous studies about techniques utilizing nanoparticles, their characteristics,
bioavailability and toxicity in vivo and in vitro. (Borisova et al. 2011, Silva et al. 2011,
Farokhzad et al. 2009)
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Drug-carrying is the main adaptation of the nanoparticles in pharmaceutical research. To
date, toxicity and low tissue selectivity are challenges in drug design. Nanoparticles provide
an alternative solution to these problems. In optimal case nanoparticles, loaded with the
drug molecules, carry the cargo to its target site. This prevents the undesirable distribution
of the drug to the other organs and significantly decreases the drug dose needed,
diminishing side effects. (Serda et al. 2011, Farokhzad et al. 2009) Several nanoparticle based
drugs carriers have been developed. However, the basic conception is notably the same. A
model example is a study by Ferris et al in which hydrophobic drugs were loaded into
mesoporous silica nanoparticles. The surface of the particles was coated with transferrin and
cyclic peptides, which acted as tumor targeting agents. This enabled successful selective
transportation of the drug molecules to the cancer cells. (Ferris et al. 2011)
Nanoparticles can be administered via different routes: orally, intravascularly or by
inhalation for lung delivery. Oral route has been the most popular for drug administration
due to its easiness. However, the harsh environment of the stomach, minimal tissue
selectivity and the need for good permeability properties are the disadvantages of this
route, especially for protein and peptide based drugs. (Coppi et al. 2008, Anal et al. 2003, Li
et al. 2008) Several various microparticles and beads have been previously designed for
enhanced oral drug delivery. Coppi et al used microparticles composed of chitosan and
alginate for peptide delivery. Anal et al studied similar chitosan/alginate beads that
protected protein based drugs from acidic conditions. However, nanoparticles in the oral
administration are not widely used. (Coppi et al. 2008, Anal et al. 2003)
Intravascular administration route is preferred in nanoparticle studies. It allows the particles
rapidly distribute to the various parts of the body via circulation. This increases the
possibilities of developing target specific nanoparticle drug carriers as well as decreases the
dose. The major disadvantage of the intravascular route is the rapid removal of the
nanoparticles from the circulation. The complement system recognizes nanoparticles as
foreign components and eliminates them via opsonisation (chapter 3.3). Important part of
nanoparticle research is developing particles invisible to MPS and increasing the circulation
time. (Owens et al. 2006, Serda et al. 2011)
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Bioimaging is another field of nanoparticle research. Particles are labelled with various
imaging molecules such as fluorescent labels and radioactive isotopes or as in the case of
gold nanoparticles, they can be directly monitored without further labelling due to their
optical properties as reviewed by Kennedy et al (2011). Bioimaging is used in studying in vivo
biodistribution of the particles for analyzing the effectiveness, toxicity and excretion of the
particles.
Diagnosis of the diseases such as tumors and inflammatory sites is another important field of
imaging with the nanoparticles. Molecules which target to the damaged tissues or mutated
cells are conjugated onto the surface of the fluorescent- or radiolabeled nanoparticles. After
administration the particles will accumulate into the disease site. The damaged tissues are
located by monitoring of the fluorescence or radiation of the particles. As an example Ozgur
et al produced technetium-labeled albumin nanoparticles with pheophorbide-a for site-
specific tumor imaging. The particles showed high uptake especially in breast cancer cells.
(Ozgur et al. 2012) In another bioimaging example, Keliher et al designed radiolabeled
dextran coated nanoparticles to analyze macrophage behaviour in vivo. They are utilized in
detecting inflammatory sites of various diseases. (Keliher et al. 2011)
3. Challenges in nanoparticle research
  3.1 Toxicity
In both pharmaceutical purposes and bioimaging experiments, potential toxicity of the
particles is the main concern and all the possible harmful effects of nanoparticles are not
known. In order to design a functional carrier molecule-drug complex, both components
naturally have to be non-toxic. Some nanoparticles cause inflammations, infections and
other unwanted side effects. Basic attributes of the particles such as material, size, shape
and solubility affect their toxicity. Silver nanoparticles are known to be cytotoxic and able to
induce inflammations and even gene mutations. Obviously, particles with this amount of
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toxicity cannot be used in drug delivery. (Huang et al. 2011, Chrastina et al. 2010, Bimbo et
al. 2010, Farokhzad et al. 2009)
To  determine  the  toxicity  of  the  nanoparticles,  special  cytotoxicity  studies  are  carried  out
before any in vivo studies are performed. These in vitro experiments are performed by using
cultured cells that are treated with the nanoparticles over the time. Toxicity is analyzed from
the decreased cell viability and ATP production which correspond to the amount of living
cells. Caco-2, HeLa and HepG2 are widely used cell lines in these kinds of cytotoxicity tests
but also macrophages are utilized. (Tian et al. 2011, Lee et al. 2010, Bimbo et al. 2010)
However, in vitro cytotoxicity studies do not completely prove the non-toxicity of
nanoparticles. As mentioned above, particles may induce various mutations and
inflammations especially in organs where the particles tend to accumulate, mostly to liver,
spleen and lung. (Liu et al. 2009) One reason for the inflammation caused the nanoparticles
is the elimination from the system by macrophages which are able to produce inflammatory
mediators when their receptors are over-expressed. (Passirani et al. 1998) These harmful
side effects are usually detected only in in vivo studies after cytotoxicity tests.
  3.2 Aggregation
Aggregation is a spontaneous process where particles are clustering. They attach to each
other leading to a formation of a larger particle due to the various interactions between the
particles, mainly electrostatic interactions and van der Waals forces as shown by Bagwe et
al. Other factors are steric interactions and the surface structure of the particle. Also the
environmental factors such as temperature, pH and the suspension solution may induce
aggregation. (Liu et al. 2012, Bagwe et al. 2006)
The particle aggregates have different characteristics compared to the original particles
mainly due to their considerably larger size interfering in vivo experiments. Their
electrostatic characteristics and affinity may also be changed. These have a significant
impact on biodistribution causing incorrect results. However, aggregation can often be
prevented by choosing suitable conditions, suspension solution, concentration and pH.
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Aggregation can be prevented with correct handing (washing, sonication) of the particles.
(Bimbo et al. 2010, Liu et al. 2012, Bagwe et al. 2006)
  3.3 Opsonisation
Opsonisation is one of the major interfering factors when using nanoparticles as drug
carriers.  It  is  a  process  where  plasma  proteins,  e.g.  opsonins,  attach  to  the  surface  of  the
particles and begin to activate macrophages, which belong to the mononuclear phagocyte
system (MPS). Activation eventually leads to the elimination of the particles and the drug
they are carrying. Opsonisation is a part of the complement system, body’s immunological
response to foreign material. Main purpose of the MPS is to eliminate foreign and infectous
components  such  as  bacteria  and  viruses  as  well  as  mutated  or  damaged  self  tissues.  As
nanoparticles  are  not  part  of  the  system,  they  are  removed  through  opsonisation  and
macrophage uptake. (Carroll et al. 2011, Sjöberg et al. 2009)
Opsonins work by covering the foreign component by attaching to its surface. After the
component is opsonized it stays in circulation until it encounters a macrophage which
recognizes the bound opsonins via surface receptors. This leads to the ingestion and
destruction of the component. Since the number of macrophages is very high in the organs
of mononuclear phagocyte system, especially in the liver and spleen, most of the opsonised
components, including nanoparticles, rapidly accumulate and are destructed. (Carroll et al.
2011, Sjöberg et al. 2009)
Almost  all  opsonins  are  found  in  circulation,  the  most  common  ones  being  fibrinogen,
human serum albumin, laminin and many so called C-type proteins (C3, C4, C5).
Immunoglobulins are also considered as opsonins even though they don’t work via the same
complement pathway as the other opsonins. Although the blood proteins involved in
opsonisation are well-known, the mechanisms how they recognize all the foreign
components are not yet fully understood. There are several complement activators i.e. C1q
and C4b and factor H involved in MPS. (Owens et al. 2006, Rytkönen et al. 2011, Sjöberg et
al. 2009)
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MPS recognizes nanoparticles as foreign components via opsonisation. Avoiding the
opsonisation by inhibiting the binding of the opsonins is crucial when designing efficient
nanoparticle based drug carriers. There are a high number of studies describing different
methods to interfere opsonisation, many of them utilizing various polymers, polysaccharides
or peptides conjugated to the surface of the nanoparticles. (Chauvierre et al. 2004, Parveen
et al. 2011, Tian et al. 2011, Hou et al. 2011, Socha et al. 2009, Poon et al. 2011) General
ideas are to reduce the interactions between the particles and the blood proteins to the
minimum by altering the physicochemical properties of the particles. These include surface
charge, hydrophilicity, van der Waals forces as well as particle size. However, no technique
or surface modification to completely avoid opsonisation has been found. (Owens et al.
2006, Rytkönen et al. 2011)
4. Surface modifications
The surface chemistry of the nanoparticles has a great impact on their pharmacokinetics.
Surface area, charge (zeta-potential), hydrophilicity, functional groups on surface, affinity
and selectivity are all characteristics that influence the bioavailability of the particles. By
altering these properties the particles are modified more efficient drug carriers. Generally,
the focus of surface modifications has two main aspects: the selectivity of the particles i.e.
into which organ or tissue they accumulate, and avoiding all the unfavourable
immunological responses of the body.
  4.1 Target specificity
Reaching the correct target tissue, usually tumor, is one of the main focuses on the surface
modifications of nanoparticles. There are only few nanoparticles that are target specific
without surface modifications. In some studies gold nanoparticles have achieved tumor
selectivity without altering their surface structure. (Kennedy et al. 2011) Some selectivity has
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been obtained by utilizing the slightly lower pH of cancer cells compared to normal tissues. It
is also possible to utilize so called passive targeting, which is based on specific size of the
nanoparticles.  (He  et  al.  2010  and  2011)  However,  no  remarkable  breakthrough  has  been
achieved without attaching effective targeting agents to the particle surface.
Selectivity of the nanoparticles is improved by conjugating various targeting molecules such
as antibodies, peptides or other specific ligands onto the surface via covalent bonding or
adsorption. The suitable targeting moiety depends on the target tissue or cell. Generally, the
selectivity is based on receptor-ligand interactions. Ferris et al used transferrin and cyclic-
RGD peptides (arginine-glycine-aspartic acid) conjugated to silica nanoparticles in tumor
targeting since their receptors are overexpressed in several types of cancer cells. (Ferris et al.
2011)  Widely  used  targeting  agents  are  organic  molecules  that  already  exist  in  system  as
they usually are non-toxic, biodegradable and stable in wide range of pH. Furthermore, they
don’t cause immunological responses. Serum proteins such as albumin, dopamine in brain
delivery, even single-stranded DNA has been used. (Trapani et al. 2011, Fujita et al. 2012,
Ozgur et al. 2012) Heparin is another molecule used as a targeting agent since several
system proteins including growth factors have heparin binding domains. (Chung et al. 2006)
Targeting agents are usually used together with other surface modifications since in most
cases they don’t prevent opsonisation or other immunological responses of the system and
nanoparticle-target agent complex is eliminated from the system before it reaches its target
tissue. To avoid fast neutralisation nanoparticles are shielded with moieties such as
polyethylene glycol or polysaccharides which protect the particles from the complement
system.  (Trapani  et  al.  2011,  Parveen  et  al.  2011,  Tian  et  al.  2011,  Rytkönen  et  al.  2011)
According  to  the  study  by  Hou  et  al  (2011),  chitosan  nanoparticles  were  coated  with
methoxypoly(ethylene glycol) as a shielding moiety and folic acid as a tumor targeting agent.
  4.2 Polyethylene glycol
One of the most widely studied surface modifications of nanoparticles is PEGylation, in
which the particles are coated with polyethylene glycol (PEG) chains or its copolymers such
as polypropylene glycol or oleyl-PEG (figure 2.). PEG is a flexible hydrophilic polymer that has
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close to neutral charge which reduces both covalent and electrostatic interactions between
PEG-molecules and opsonins as well as other systemic proteins. PEG is also non-toxic and
causes no immunological response improving further its usefulness in surface modifications
of nanoparticles (Owens et al. 2006, Parveen et al. 2011, Rytkönen et al. 2011, Hou et al.
2011)
Figure 2. The structures of polyethylene glycol (PEG) and two of its copolymers: polypropylene glycol
and  oleyl alcohol linked PEG (O-PEG)
PEG can be attached to the particles with either covalent bonds, adsorption or by entrapping
PEG moieties within the surface. (Owens et al. 2006) The most suitable PEGylation method
depends on the type of particles; adsorption for example works well if the particle surface is
hydrophobic. (Rytkönen et al. 2011) Generally, the differences in results between these
methods are not remarkable. There are some studies suggesting that adsorption of PEG
provides more comprehensive coverage around the particles while some research suggest
that covalently bound PEG increases the circulation time more than other methods. While
each PEGylation method has its advantages, desorption of adsorbed PEG-molecules or
incomplete coverage of covalently attached PEG may decrease the shielding efficiency.
(Owens et al. 2006, Parveen et al. 2011, Rytkönen et al. 2011, Bazile et al. 1995)
The main application of PEGylation is to increase the circulation time of the particles by
blocking opsonisation. There are several studies showing that PEG or its copolymers
decrease the amount of plasma proteins binding to the surface of the particles, thus
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improving the evasion of the MPS-macrophages. (Parveen et al. 2011, Rytkönen et al. 2011,
Huang et al. 2011, He et al. 2011) The circulation half-life of PEGylated particles, and a drug
molecule carried by them, has been successfully extended from few hours up to several days
as  shown  by  Parveen  et  al. However, since PEG and its copolymers have no biotargeting
abilities, surface conjugated PEG molecules cause no accumulation of particles to a specific
organ, tissue or tumor. Hou et al showed that a copolymer of PEG, methoxypoly(ethylene
glycol)  (mPEG)  does  not  have  the  ability  to  increase  the  tumor  specificity  or  intracellular
delivery capabilities of the particles; PEG polymers increase passive tumor targeting due to
the longer blood half-life. (Hou et al. 2011) In conclusion, PEG should be used in conjugation
with efficient biotargeting molecules.
  4.3 Polysaccharides
Polysaccharides  are  other  widely  studied  polymers  for  particle  shielding.  They  are  long
chains composed of repeating carbohydrate units linked to each other via covalent glycosidic
bonds, either linearly or branched. While there is usually little to no variation between the
building blocks of polysaccharides, the length of the chains vary considerably from a couple
of hundred to thousands of units. Polysaccharides can be either synthetic or derived from
nature i.e. alginate from brown algae. (Díaz-Barrera et al. 2011, Varki et al. 2008)
The main characteristics of the polysaccharides, affinity and charge, depend on the length of
the chain but more on their functional groups, mainly amines, carboxyls and sulphates.
Polysaccharides such as alginate with carboxylic acid groups are negatively charged and
acidic. (Cai et al. 2012, Díaz-Barrera et al. 2011) Polysaccharides with amine groups like
chitosan are respectively positively charged due to their ability of being protonated. (Tavares
et al. 2011) There are also some neutral polysaccharides, like dextran which have none of
the functional groups mentioned above, that can be used for crosslinking or shielding agent
in a similar way as PEG. (Passirani et al. 1998, Keliher et al. 2011)
In shielding nanoparticles, polysaccharides offer a versatile option to polyethylene glycol or
its copolymers. The presence of functional groups in polysaccharide chains allows further
modifications of the particles, for example crosslinking or conjugating more polymers. For
the  same  reason,  the  coating  can  be  performed  either  covalently,  with  anionic  or  radical
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polymerization or via electrostatic forces called layer-by-layer technique (LbL). Each method
results different characteristics of the shielding, stability and affinity. In addition, conjugating
targeting moieties onto the surface of the particles is easier with polysaccharide coated
particles than with PEGylated particles due to the functional groups of the polysaccharides.
(Lemarchand et al. 2006, Lemarchand et al. 2004, Zhou et al. 2010, Hou et al. 2011)
Natural polysaccharides have recently received much attention because of their
biocompatibility, biodegradability and low toxicity. Most common ones are alginate which
has good crosslinking and gel-forming abilities and chitosan due to its positive charge and
mucoadhesive properties. (Lemarchand et al. 2004, Cai et al. 2012, Shi et al. 2005) Heparin,
another common polysaccharide, has anticoagulant properties and highly negative charge as
well as possibility to use as targeting agent. (Chauvierre et al. 2004, Chung et al. 2006,
Wuang et al. 2006) Several other polysaccharides have been tested such as sialic- and
hyaluronic  acids,  gelatine  or  dextran  but  no  conclusions  can  be  made  to  select  the  most
effective polysaccharides in nanoparticle shielding. (Lemarchand et al. 2004, Keliher et al.
2011, Hu et al. 2010)
  4.4 Layer-by-layer assembly
Layer-by-layer (LbL) is a method, where several layers composed of polyelectrolytes of
opposite charges are added onto the surface of a particle. After depositing one
polyelectrolyte layer onto the object, another layer of opposite charge is added until a
desired  amount  of  polyanion  and  polycation  layers  is  reached.  Lbl  is  one  of  the  most
commonly used noncovalent surface modification method since it is based on electrostatic
interactions instead of covalent bonding and a large number of various polyelectrolytes can
be used to compose the layers. Generally, all polymers with sufficient positive or negative
charge can be utilized allowing high versatility of lbl-assembly. (Zhou et al. 2010, Hu et al.
2010)
With  nanoparticles  there  are  two  main  aims  to  use  lbl  assembly:  to  increase  biotargeting
abilities by improving their target specificity and to increase the circulation time of the
particles by preventing opsonisation. The former can be achieved by using targeting agents
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together with lbl-assembly. The various functional groups within the polymers used in lbl
allow targeting moieties to be conjugated to the lbl-particle complex. In a study of Zhou et al
(2010) chitosan and alginate layers were composed around nanoparticles and folic acid as a
targeting agent was conjugated to the layers via carbodiimide chemistry.
Opsonisation of the particles can be reduced by creating a sufficient lbl-shield around the
particles. The number and the density of the layers determine the shielding efficiency, but
also the charge of the outermost layer has impact on opsonisation; neutral charge reduces
the binding affinity of the opsonins. (Owens et al. 2006, Zhou et al. 2010, Haidar et al. 2008)
There are also studies about utilizing crosslinking of the layers to increase the shielding
effect. (Anal et al. 2003, Li et al. 2008) As studied in the experimental section of this thesis, a
drawback of this method is that it is often difficult to compose layers with sufficient density
that are stable in various conditions in the body. Composing a high number of layers tend to
decrease the stability of the layers and increase aggregation of the particles.
  4.5 Crosslinking
Crosslinking is a technique where molecules, usually polymers chains or proteins, are linked
to each other to create an extensive network of molecules and alter their characteristics. A
crosslinking bond can be formed if there are suitable functional groups such as carboxylic
acids, primary amines or sulfhydryls present. The links are formed by altering temperature or
pH, or using special crosslinking reagents. (Pierce Biotechnology Inc, Crosslinking reagents
technical handbook 2006) The crosslinks are induced ionically by utilizing electrostatic
interactions between the molecules, or more commonly chemically by synthesizing the link
via covalent bonds (figure 3). Iron(III)- and calcium ions are examples of widely used ionic
crosslinkers. (Coppi et al. 2008, Keliher et al. 2011, Shi et al. 2005) Common chemical
crosslinkers are glutaraldehyde and carbodiimides such as EDC (1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide). (Hou et al. 2011, Crosslinking reagents technical
handbook 2006)
Crosslinking is widely used both in industry and research. Perhaps the most well-known
application is gels, which is used in countless number of products starting from hair dye to
drug delivery systems. Vulcanization is another one of the most common methods to utilize
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crosslinking, mainly in rubber industry. It is a technique to form links between polymer
chains, usually polyisoprene, by adding suitable crosslinking agents such as sulphur or
peroxides to increase durability and elasticity of the crosslinked material (figure 3). (Engels et
al. 2004)
In biochemistry, crosslinking has a high number of applications. Crosslinking can be used to
locate  and  identify  proteins  and  amino  acids  within  the  cell  membranes  and  on  the  cell
surface. The interactions between various proteins or receptors and ligands can also be
studied by utilizing crosslinking. There are also some studies in which crosslinking has been
used to achieve a more sustained release of growth factor which is polypeptide. (Tanihara et
al. 2001) Furthermore, techniques such as sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) exploit the crosslinking chemistry. (Shi et al. 2005, Crosslinking
reagents technical handbook 2006)
There are a number of studies about crosslinking techniques with micro- and nanoparticles.
Hou et al described methods to attach chitosan to nanoparticles without using layer-by-layer
technique. This method is based on covalent bonds rather than electrostatic interactions.
(Hou et al. 2011) Zeng et al studied the influence of crosslinking on the interactions between
the nanoparticles and the shielding polysaccharides, mainly heparin, and suggests that
crosslinking decreases the flexibility of the polymer chains while contributing to high affinity.
(Zeng et al. 2011) Generally, the main aim of crosslinking is to enhance the shielding effect of
polymers. Keliher et al incorporated dextran chains into the surface of nanoparticles and
strengthened them via crosslinking with epichlorohydrin, while Liu et al used the same
principle with oleoyl-chitosan and sodium tripolyphosphate as a crosslinker reagent to
produce nanoparticles for oral delivery of proteins. (Ya et al. 2011, Keliher et al. 2011)
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  4.6 Radiolabeling
Radiolabeling nanoparticles requires different surface modification compared to PEGylation
or layer-by-layer assembly, since the purpose is not to alter the characteristics and
behaviour of the particles. Radioactive isotopes are conjugated to the surface of the
nanoparticles in order to monitor biodistribution of the particles without changing their
pharmacokinetics.
There are several isotopes that can be used in radiolabeling for imaging. The choice of
suitable radionuclide depends on the labelling procedure that does not alter properties of
the nanoparticles. Widely used tracers are technetium-99m, indium-111 and iodine isotopes
Figure 3. The two crosslinking methods. Vulcanization as an example of covalent crosslinking (a)
and respectively forming alginate gel as an example of ionic crosslinking (b).55, 56
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like I-123 and I-125. (Ozgur et al. 2012, Chrastina et al. 2010, Kumar et al. 2010, Liu et al.
2009) With positron emission topography (PET), nuclear imaging technique based on
emitted positrons, nuclides such as fluorine-18, bromine-76 and copper-64 can be utilized.
(Rossin et al. 2008) Bimbo et al (2010) labelled porous silicon nanoparticles with 18F in order
to obtain high radioactivity while not changing the particle size or surface structure and
therefore their in vivo behaviour. Liu et al (2009) used 76Br in polyacrylamide hydrogel
nanoparticles.
With nanoparticles, wide range of both radio isotopes and the labelling methods are used.
Generally, in order to maintain the characteristics of the particles, the exact labeling site and
mechanism must be known. Usually specific small linker molecules are used to facilitate the
radiolabeling. Rytkönen et al (2011) and Liu et al (2009) conjugated iodine isotopes via
tyrosine residues. Other typical methods include coordination chemistry and chelates with
technetium-99m and zirconium-89 (Ozgur et al. 2012, Keliher et al. 2011) or substitution of
hydrogen atom by tritium or a halogen isotope. (Lemarchand et al. 2006, Liu et al. 2009)
Instead of radiolabeling fluorescence emitting molecules, such as FITC (fluorescein
isothiocyanate) are often used, especially in in vitro experiments, where the intracellular
biodistribution is followed by fluorescence. (Parveen et al. 2011, Arora et al. 2011, Hou et al.
2011, Huang et al. 2011, He et al. 2011)
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EXPERIMENTAL SECTION
Introduction
Mesoporous silicon nanoparticles have been widely studied as targeted drug carriers. They
can be loaded with different types of therapeutic agents, while their properties such as
surface chemistry determines their characteristics and behaviour in system. However,
nanoparticles are rapidly removed from the circulation due to the opsonisation, where
several plasma proteins bind onto the surface of the particles, leading to macrophage uptake
and elimination. The circulation time of the particles may be increased by shielding them
with polymers such as polyethylene glycol or with polysaccharides, which affect to the
biodistribution of the nanoparticles by blocking the binding of the plasma proteins. The
shielding effect may be improved by increasing the number of layers by using
polysaccharides of opposite charges.
The purpose of the study
In this Master’s Thesis, mesoporous silicon nanoparticles coated with various
polysaccharides (chitosan, alginate and heparin) by using layer-by-layer technique in order
to decrease the opsonisation rate and the macrophage uptake of the particles was studied.
The effect of crosslinking the polysaccharide layers is studied. The opsonisation rate and
stability of the lbl-nanoparticles are tested in vitro, followed by radio-labelling with 125I-
isotope and in vivo –experiments with mice to study the biodistribution and accumulation of
the particles.
27
5. Materials
  5.1 UnTHCPSi-nanoparticles
UnTHCPSi-particles are thermally hydrocarbonized porous silicon nanoparticles which are
treated with undecylenic acid to form carboxylic acid groups on the surface of the particles
(figure 4.). This enables further surface modification of the particles. UnTHCPSi-particles
used in this study were received from the Department of Physics in the University of Turku
(Dr. Jarno Salonen). Two different batches were used, the size of the particles varied from
135 to 150 nm. The initial zeta-potential of the particles was around -30 mV.
Figure 4. Surface structure of the UnTHCPSi-nanoparticles
  5.2 TCPSi-NH2-nanoparticles (amino particles)
TCPSi-NH2-particles are porous silicon nanoparticles which are thermally carbonized with
primary amino groups on the surface (figure 5.). TCPSi-NH2-particles were formed by
oxidizing carbide surface with ammonium hydroxide and hydrochloric acid, and
functionalized with 3-(2-Aminoethylamino) propyldimethoxymethylsilane (AEASP). The initial
size of the TCPSi-NH2-particles  was  170  nm  and  the  zeta-potential  +69  mV.  The  particles
were produced in the Department of Applied Physics in the University of Eastern Finland
(prof. Vesa-Pekka Lehto).
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Figure 5. Surface structure of the TCPSi-NH2-particles.
  5.3 Chitosan
Chitosan (chi) is a linear polysaccharide composed of glucosamine and N-acetyl-glucosamine
blocks (figure 6). It is derived from deacetylation of chitin, a typical structural element of
crustacean shells. It is nontoxic, biodegradable and –compatible, and therefore usable in
pharmaceutics. Furthermore, chitosan’s positive charges through protonation of its amino
group enhance mucoadhesive characteristic and permeability through different membranes
or epithelial surfaces. (Tavares et al. 2011, Tian et al. 2011, Ya et al. 2011)
Chitosan used in this study has low molecular weight, 50-190 kilodaltons, with deacetylation
percent of 84,5 (Aldrich, Steinheim, Germany).
  5.4 Alginate
Alginate (alg), or alginic acid, is an anionic linear biopolymer, which is composed of two
different polymers, ?-L-guluronate and ?-D-mannuronate (figure 6). It is usually derived
from brown algae such as seaweed, but it is also produced by some types of bacteria,
Azorobacter vinelandii for instance. Like chitosan, alginate is biodegradable and –compatible
polysaccharide with an advantage of being non-immunogenic. Alginate is hydrophilic due to
its several carboxyl groups; it has high negative charge and therefore is capable of absorbing
water quickly and entrap various molecules. For the same reason, alginate is utilized in
creating polyelectrolyte layers. (Cai et al. 2011, Díaz-Barrera et al. 2011, Shi et al. 2005)
Alginate used in these experiments is derived from brown algae. It is in sodium salt form and
has medium viscosity with molecular weight of 80-120 kDa (Aldrich, Steinheim, Germany).
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  5.5 Heparin
Heparin (hepa) is a glycosaminoglycan composed of various sulphated disaccharide units
such as D-glucosamine and uronic acid (figure 6.). Although the length and structure of the
polysaccharide chains of heparin vary, it is always highly negatively charged due to the
sulphated residues, allowing it to be used in forming negative polysaccharide layers. Heparin
is extracted from various tissues, like liver and lung for, most common source being porcine
intestinal mucosa. Heparin is anticoagulant and –thrombic and interacts with various
proteins including several growth factors. It has been widely studied and used for
pharmaceutical purposes. (Chung et al. 2006, Cosmi et al. 2011)
Heparin (Sigma-Aldrich, Steinheim, Germany) of this study is sodium salt form and derived
from porcine intestinal mucosa. Its molecular weight varies from 5 to 30 kDa.
Figure 6. Structures of chitosan, alginate, heparin and building blocks. Heparin may consist of various
sulphated disaccharide units, therefore having several different possible structures.
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6. Layer by layer (LbL) coating
For the LbL studies both carboxylic acid derivated mesoporous nanoparticles (UnTHCPSi)
with negative surface charge and positive charged primary amino derivated nanoparticles
(TCPSi-NH2) were used.
Nanoparticles were coated with polysaccharide layers using layer by layer (LbL) technique, in
which each polysaccharide layer was added to the layer below via electrostatic interactions
using the polysaccharides of opposite charges, a negatively charged polysaccharide layer was
added on the positively charged layer and vice versa. Chitosan was used to compose positive
layers, while negative layers were formed by using either alginate or heparin. For the
negatively charged UnTHCPSi-particles, the first polysaccharide layer was chitosan. The first
layer for the positively charged amino derivated particles was either alginate or heparin.
  6.1 LbL formation
In order to add each polysaccharide layer, 300 µg of nanoparticles were suspensed into 750
µl  of  washing  solution,  which  usually  was  either  acetate  buffer  (10  mM  AcOH;  pH  4,5)  or
sodium chloride (0,5 M NaCl; pH 5, adapted from Zhou et al. (2010)). 750 µl polysaccharide
solution (1mg/ml in washing solution) was added drop wise to the particle suspension while
maintaining continuous sonication (Branson 2510E-MT, Danbury CT, USA). The suspension
was incubated for 20 minutes at room temperature, followed by 20 minutes centrifugation
using 13200 rpm (Eppendorf Centrifuge 54154, Germany) to remove the excess reagents.
Finally, the particles were washed three times with 1 ml of washing solution. Before adding
the next polysaccharide layer, an aliquote of 50 µg of nanoparticles were taken in order to
measure the size and ?-potential in water with dynamic light scattering (Malvern Zetasizer
Nano-ZS). The produced lbl-particles are listed in table 1.
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Table 1. Layer by layer nanoparticles produced.
Particle                      Outermost layer
UnTHCPSi + 5 layers of chitosan and alginate                      Chitosan
UnTHCPSi + 5 layers of chitosan and alginate crosslinked                Chitosan
UnTHCPSi + 6 layers of chitosan and alginate                      Alginate
UnTHCPSi + 6 layers of chitosan and alginate crosslinked                Alginate
UnTHCPSi + 5 layers of chitosan and heparin                      Chitosan
UnTHCPSi + 5 layers of chitosan and heparin crosslinked  Chitosan
UnTHCPSi + 6 layers of chitosan and heparin  Heparin
UnTHCPSi + 6 layers of chitosan and heparin crosslinked  Heparin
TCPSi-NH2 + 6 layers of alginate and chitosan  Chitosan
TCPSi-NH2 + 6 layers of alginate and chitosan crosslinked  Chitosan
  6.2 Crosslinking
After the final layering, both 5-layered and 6-layered nanoparticles were crosslinked (cl). 1-
Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC; Aldrich, Steinheim, Germany) and N-
hydroxysuccinimide (NHS; Fluka, Buchs, Switzerland), dissolved in 2-(N-morpholino)
ethanesulfonic acid (MES; pH 6), were used to link polymer chains to another. EDC activates
carboxyls of alginate or heparin to react with primary amine groups of chitosan chains
leading to formation of amide bonds, while NHS increases the coupling efficiency of the
reaction by forming a less labile activated acid. Layer-by-layer nanoparticles were washed
twice with MES before being suspensed into a solution containing 10 mM EDC and 10 mM
NHS in 1 ml of MES. The suspension was mixed with an end-over-end -mixer (BIOSAN
Biorotator RS-Multi, Labema, Kerava, Finland) at room temperature for either 1 hour or
overnight in order to see if incubating time has any effect on crosslinking efficiency. The
crosslinked particles were washed twice with distilled water, after which a sample of
nanoparticles were taken to size and ?-potential measurements.
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7. Stability of the layer-by-layer particles
  7.1 Stability
In order to study the stability of the polysaccharide coating (chitosan and alginate) and the
aggregation of the particles, five layered UnTHCPSi-nanoparticles, six layered TCPSi-NH2-
particles and their crosslinked versions were suspensed into various buffer solutions
including hydrochloric acid (HCl; 2 M), phosphate buffered saline (PBS; pH 7,4) and 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; 10 mM; pH 7,4). 100 µg of the
nanoparticles were suspensed into the buffer solution and incubated for one hour, four
hours or overnight. The size and ?-potential of the particles were measured in water before
and after the incubation.
  7.2 Long term stability
The long term stability of six layered UnTHCPSi-particles, made by using either acetate buffer
or sodium chloride, and their crosslinked versions was studied in water. 250 µg of particles
were suspensed into 1 ml of water and stored at +4 oC for two weeks. During storage the
size and ?-potential of the particles were measured seven times at time points of three, four,
five, seven, ten, twelve and fourteen days.
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8. Opsonisation tests
  8.1 Plasma tests
The stability and the opsonisation rate were tested in vitro by using 50 % human EDTA
(ethylenediaminetetraacetic acid) -plasma in PBS; pH 7,4. Layer by layer nanoparticles and
untreated original particles as a control were suspensed into plasma solution and incubated
at +37 oC for 15 minutes as majority of opsonins bind to the particles within minutes. After
the incubation, the particles were washed twice with water before taking a sample of 50 µg
of particles to size and ?-potential measurements.
  8.2 Electrophoresis
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed in
order to characterize the opsonins bound to the surface of the nanoparticles. Opsonized
nanoparticles, 50 µg per sample, were mixed with 15 µl of SDS-PAGE sample buffer (125mM
Tris-HCl  pH  6.8,  2  %  SDS,  5  %  glycerol,  0.002%  bromophenol  blue)  and  incubated  for  5
minutes at +100 oC  with  a  block  heater.  The  nanoparticle  samples  along  with  a  250  kDa
molecular marker and a sample containing only plasma in water (1:200) were then added to
the  10  %  acrylamide  gel,  15  µl  per  well,  and  run  for  two  hours  with  100  V  and  400  mA.
Finally,  the  gel  was  stained  with  0,025  %  Coomassie  Brilliant  Blue  (Thermo  Scientific)  for
overnight at +4 oC and washed with water.
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9. Radio-labelling of the nanoparticles
  9.1 UnTHCPSi-particles
  9.1.1 Tyrosine conjugation
In order to facilitate the radio-labelling of the UnTHCPSi-nanoparticles, tyrosine (tyr) (figure
7.)  was  first  conjugated  to  the  surface  of  the  nanoparticles  via  an  amide  bond.  40  mM  of
N,N’-diisopropylcarbondiimide (DIC; PerSeptive Biosystems GmbH, Hamburg, Germany) and
NHS were added to activate the carboxylic acid groups of the UnTHCPSi-particles. The
suspension was sonicated until the particles are evenly dispersed in the solution, and mixed
with the end-over-end –mixer for one hour at room temperature. In order to remove the
excess of activation reagents, the nanoparticle suspension was washed three times with 1 ml
of acetonitrile followed by 15 minute centrifugation time. Activated nanoparticles were
suspensed into 670 µl of L-tyrosine solution (0,3 mg/ml in H2O; Sigma, Steinheim, Germany),
the volume was added to 1 ml with acetonitrile, and the suspension was mixed with the end-
over-end –mixer for overnight at room temperature. Finally, the excess reagents were
removed by washing the suspension three times with water as described above.
  9.1.2 Iodination of the nanoparticles
Five and six layered UnTHCPSi-nanoparticles, including both crosslinked and non-crosslinked
particles, and unmodified tyrosinated particles were radio-labelled with 125I-isotope by using
Pierce Iodo-Gen iodination tubes (Thermo Scientific, Rockford IL, USA). The Iodo-Gen tubes
were  first  rinsed  with  1  ml  of  HEPES  (10  mM;  pH  7.4).  90  µl  of  HEPES  and  3-3.5  MBq  of
Na125I-solution (MDS Nordion, Fleurus, Belgium) were added to the tube and incubated for
ten minutes at RT. A suspension containing 150 µg of nanoparticles in HEPES was added to
the iodination tube, followed by 20 minutes incubation time during which the tube was
swirled gently every three minutes. The suspension was moved into a 2 ml eppendorf tube.
The iodination tube was washed with 500 µl of HEPES and the washing solution was added
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on  the  nanoparticles.  Finally,  the  particles  were  washed  three  times  with  HEPES  with  15
minutes centrifugation time (13200 rpm). The total radioactivity of the samples was
measured with a radioisotope calibrator (Capintec Radioisotope Calibrator CRC-120,
Capintec inc. Ramsey NJ, USA) before and between each wash.
  9.2 TCPSi-NH2-nanoparticles
  9.2.1 Phloretic acid
Since TCPSi-NH2-nanoparticles don’t contain carboxylic acid, phloretic acid (phl) (3-(4-
hydroxyphenyl) propionic acid; Aldrich, Steinheim, Germany) was used instead of tyrosine to
facilitate the iodination (figure 7.). 300 µg of amino particles were suspensed into 190 µl of
phloretic acid solution (0,3 mg/ml in H2O). 40 mM of DIC and 40 mM of NHS were added to
activate the carboxylic acid groups of the phloretic acid. Total volume was increased to 1 ml
with water and the suspension was mixed with the end-over-end –mixer overnight at room
temperature. The excess reagents were removed by washing the particles thrice with water
using 15 minutes centrifugation.
  9.2.2 Iodination
The iodination of the amino particles was carried out as described above with the UnTHCPSi-
particles.  However,  since  HEPES  precipitated  the  particles,  the  iodination  was  made  in
deionized water. Four different kinds of particles were radio labelled including original
particles, amino particles with phloretic acid and six layered particles, both untreated and
crosslinked ones. The radioactivity of the particles was measured after labelling and each
wash.
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Figure 7. The structures of tyrosine (left) and phloretic acid (right), and their iodinated versions. Also,
di-iodo molecules, in which both meta positions of the phenol ring are iodinated, can occur.
  9.3 Stability of the radiolabeled particles
The stability of the radiolabeled particles was tested in human plasma. Nanoparticles were
centrifuged for 15 minutes using 13200 rpm and the supernatant was removed. The particles
were suspensed by sonication into 300 µl of plasma solution (50 % human EDTA-plasma in
PBS; pH 7,4), after which they were incubated for 30 minutes at +37 oC. The plasma solution
was removed by 20 minutes centrifugation with 13200 rpm. Finally, the particles were
washed twice with distilled water. The radioactivity of the particles was measured after each
wash.
10. Biodistribution studies
  10.1 Particle preparations
The biodistribution of the Lbl-nanoparticles in mice was studied with five different
modifications of nanoparticles: UnTHCPSi-particles with five and six polysaccharide layers,
with or without crosslinking, and particles with polyethylene glycol (PEG) adsorbed on their
surface as a control.
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For PEGylation, tyrosinated UnTHCPSi-particles were suspensed into 1 ml of water
containing  10,1  mM  O-PEG  (10  kDa,  synthesis  adapted  from  Silvander  et  al.  (2003)).  The
suspension was mixed with the end-over-end –mixer for overnight at room temperature.
Finally, PEGylated particles were washed three times with water using 15 minutes
centrifugation with 13200 rpm.
Particles were radio-labelled with 125I-isotope as described above. Finally, the particles were
suspensed  into  6,8  %  HEPES-buffer  with  a  concentration  of  1  mg  of  particles  in  1  ml  of
buffer.
10.2 In vivo experiments
30 mice from C57BL-strain were used in the studies. The mice were all healthy females
weighting  from  15  to  25  grams.  They  received  water  and  chow ad libitum with light/dark
rhythm of 12/12. The experiments were carried out according to the guidelines approved by
the Ethical Committee of the National Laboratory Animal Centre Finland (Licence number
ESLH-2009-10004/ym23, Kuopio, Finland).
The mice were anaesthetised with isoflurane before being injected intravascularly with 50 µl
of radiolabeled nanoparticle suspension (50-170 kBq). The animals were sacrificed either 10
minutes or 30 minutes after the injection with carbon dioxide. Three animals were used per
time point.
Ten various tissue samples, including blood, heart, lung, liver, spleen, kidneys, ovary, fat,
muscle and brain, were collected from each mouse into tarred gammacounter tubes. The
samples were weighted and their radioactivity was measured with gamma counter (LKB-
Wallac  Clinigamma  1272,  Wallac  Oy,  Turku,  Finland).  The  percentage  of  injected  dose  per
weight of the tissue was calculated.
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RESULTS
11. Size and zeta-potential
Surface modifications change the properties of nanoparticles, mainly size and zeta potential.
After adding each polysaccharide layer and after crosslinking, a small aliquote of 50 µg of lbl-
nanoparticles suspensed in water was taken. The size and ?-potential of the particles was
measured from the aliquote with dynamic light scattering.
Polysaccharides layers on the surface usually increased the nanoparticle size after each layer
(table 2.) especially after adding chitosan layers. In some cases negatively charged layer
decreased the size compared to the previous layer as seen especially in particles with four
polysaccharide layers. Crosslinking increased further the size of the particles.
Table 2. The  size  (in  nanometres)  of  the  layer-by-layer  nanoparticles  made  using  10  mM  AcOH  as
washing solution. After adding each layer, a sample containing 50 µg of particles in distilled water
was measured with dynamic light scattering. Crosslinking of 5-layered TCPSi-NH2-particles was not
tested.
Layer          UnTHCPSi + chi/alg           UnTHCPSi + chi/hepa             TCPSi-NH2 + alg/chi
None 144,3                   144,3                     178,4
1 169,6                   172,0   191,6
2 175,5                   169,2   220,0
3 206,2                   193,1   260,6
4 194,4                   159,3   270,7
5 214,0                   197,5   272,0
6 217,6                   183,4   335,5
5 crosslinked 245,3                   211,9       -
6 crosslinked 229,3                   229,9   356,2
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There were no significant differences in the zeta potentials between different particles,
number of the layers or the charge of the last layer (table 3.). With UnTHCPSi-particles,
positively charged chitosan layers decreased the negative ?-potential whereas negatively
charged alginate or heparin increased it. The changes in ?-potentials were considerably
smaller than expected and never rose above 0 mV. This can be due to acetate buffer used as
washing solution, which can be seen especially in TCPSi-NH2-particles. ?-potential of the
original amino particles is almost +70 mV but after adding polysaccharide layers it has
decreased to  -20 mV, staying there regardless of the charge of the added layer. Crosslinking
causes minor, but not significant, changes in ?-potential.
Table 3. Zeta potentials (mV) of the layer-by-layer nanoparticles made using 10 mM AcOH as washing
solution. Crosslinking of 5-layered TCPSi-NH2-particles was not tested.
Layer          UnTHCPSi + chi/alg           UnTHCPSi + chi/hepa             TCPSi-NH2 + alg/chi
None -25,8 -25,8 +69,3
1 -24,2 -25,5 -21,8
2 -25,0 -27,5 -21,6
3 -22,8 -20,2 -23,2
4 -23,3 -25,1 -21,7
5 -21,8 -24,4 -21,3
6 -22,7 -23,8 -17,3
5 crosslinked -22,5 -24,2     -
6 crosslinked -20,7 -24,2 -19,0
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  11.1 Sodium chloride as washing solution
In order to get more reliable zeta-potential values, UnTHCPSi-particles were coated with
chitosan and alginate layers using sodium chloride as washing solution instead of acetate
buffer (adapted from Zhou et al. (2010)).
The size and ?-potential of the lbl-particles changed significantly when sodium chloride was
used (table 4.). The changes in ?-potential values were more remarkable; adding negatively
charged alginate layer clearly increased the negative ?-potential while chitosan layers
decreased the potential back to the starting value. However, ?-potential of the lbl-particles
was never positive.
The size of the sodium chloride lbl-particles was considerably larger compared to acetate
buffer particles. This is due to the aggregation caused by sodium chloride. Also, instead of
enlarging lbl-particles, crosslinking decreased their size.
Table 4. Size (nm) and ?-potential (mV) of UnTHCPSi-particles coated with chitosan and alginate
layers composed by using either acetate buffer (AcOH) or sodium chloride (NaCl) as washing solution.
Layer Size with AcOH/NaCl ?-potential with AcOH/NaCl
1    169,6 / 211,2  -24,2 / -28,0
2    175,5 / 295,9  -25,0 / -40,9
3     206,2 / 317,9  -22,8 / -25,8
4        194,4 / 490,2  -23,3 / -46,8
5        214,0 / 411,3  -21,8 / -26,9
6        217,6 / 679,5  -22,7 / -41,5
6 crosslinked        229,3 / 623,2  -20,7 / -27,4
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12. Stability and aggregation
The stability of the polysaccharide shielding of UnTHCPSi and TCPSi-NH2 particles was tested
by  incubating  five  layered  (UnTHCPSi)  or  six  layered  (TCPSi-NH2) particles and their
crosslinked versions in various buffers including hydrochloric acid, phosphate buffered saline
and HEPES. HCl had no effect on polysaccharide layers as after four hours of incubation
there were no significant changes in the size or zeta-potential of the particles. In other words
HCl didn’t cause aggregation or changes in the layer structure. Furthermore, the lbl-particles
didn’t precipitate in hydrochloric acid. PBS caused slight aggregation and precipitation.
HEPES had no effect on UnTHCPSi-lbl-particles and therefore could be exploited in
radiolabeling and in vivo –studies. However, with TCPSi-NH2-particles slight precipitation
takes place in HEPES within one hour.
To study to stability of the polysaccharide coating, UnTHCPSi-particles were shielded with six
layers of chitosan and alginate and stored in water for two weeks at +4 oC. Four types of six
layered particles were tested: particles made in acetate buffer and particles made in sodium
chloride, and their crosslinked versions. The size and ?-potential of the particles were
measured several times during the storage. Results (figure 8.) show that the size and? ?-
potential of the lbl-particles made with acetate buffer remain roughly the same; the minor
changes are probably due to the aggregation of the particles. Sodium chloride lbl-particles
on the other hand decrease both in size and in negative? ?-potential during the two weeks,
indicating possible removal of polysaccharide layers. However, this is uncertain since the
NaCl-lbl-particles are considerably larger and aggregate easier than the AcOH-particles.
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13. Radio-labelling
Layer-by-layer or PEG coated particles with tyrosine (UnTHCPSi) or with phloretic acid
(TCPSi-NH2), as well as original particles without shielding, tyrosine or phloretic acid as
controls, were radio-labelled with iodine-125. The radiolabeling efficiency was calculated as
a percentage of the radioactivity of the bound iodine per total activity of the iodine used.
The results (table 5.) show that there were only small differences in radiolabeling of
UnTHCPSi-particles with or without tyrosine derivatisation. However, the radiolabeling
efficiency  of  the  PEGylated  particles  seems  to  be  lower  than  that  of  any  of  the  UnTHCPSi-
particles. It is possible that the PEG coating slightly prevents the radioactive iodine to bind to
tyrosine.
The radiolabeling efficiency for TCPSi-NH2-particles was clearly higher than with UnTHCPSi-
particles, roughly half of the iodine used was bound to the particles. Interestingly, using
phloretic acid decreased the radiolabeling efficiency; therefore the best labeling efficiency
was obtained with TCPSi-NH2-particles without phloretic acid, suggesting that iodine adsorbs
directly to the silicon structure of the particle. The exact position is unclear.
Figure 8. The stability of the polysaccharide coating. Six layered UnTHCPSi-particles (chi/alg), made
by using either acetate buffer (AcOH) or sodium chloride (NaCl), and their crosslinked (cl) versions
were stored at +4 oC for two weeks. The size and the zeta-potential of the particles were measured
seven times during the weeks.
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The radiolabeled particles were incubated in human plasma at +37 oC in order to determine
the stability of the radiolabel. After the incubation plasma and unbound radioactive iodine
was removed by centrifugation and two washes. The radioactivity of the particles was
measured after each wash. The plasma test showed that regardless of the type of
nanoparticles or polysaccharide coating, the radioactivity decreased roughly 25 %. The same
activity level was found also in particles without phloretic acid.
Table 5. Radiolabeling efficiencies of UnTHCPSi- and TCPSi-NH2-nanoparticles and their surface
modified versions. The percentage is the amount of radioactive iodine conjugated to the particles per
total activity of iodine added.
Particle                    Radiolabeling efficiency (%)
UnTHCPSi untreated  9,4
UnTHCPSi+tyrosine+PEG (10 kDa)  5,2
UnTHCPSi+tyr+lbl 5 chitosan/alginate 13,7
UnTHCPSi+tyr+lbl 5 chi/alg crosslinked 11,2
UnTHCPSi+tyr+lbl 6 chi/alg 12,3
UnTHCPSi+tyr+lbl 6 chi/alg crosslinked 10,9
TCPSi-NH2 untreated 57,5
TCPSi-NH2+phloretic acid 41,6
TCPSi-NH2+phl+lbl 6 alg/chi 38,5
TCPSi-NH2+phl+lbl 6 alg/chi crosslinked 45,8
14. Opsonization
  14.1 In vitro
In vitro opsonisation tests were performed by incubating lbl-UnTHCPSi-particles in human
plasma in order to determine the amount and type of plasma proteins, i.e. opsonins, bound
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to the surface of the particles. Results (table 6.) show that as expected, incubation in plasma
increased the size of the particles due to opsonins bound to the surface, but also because of
the  aggregation  of  particles.  With  lbl-particles  made  in  acetate  buffer,  the  size  of  the
crosslinked particles tends to increase less than that of untreated lbl-particles. However, the
size of some lbl-particles made in sodium chloride (NaCl-particles) decreased during the
opsonisation test. This is due to the lbl-particles being already aggregated before the
incubation. Therefore the changes of the properties of the NaCl-particles during the
opsonisation test are not reliable. Incubation in plasma causes mostly minor changes in the
zeta-potential of the particles. Nonetheless, the change is always positive, negative ?-
potential decreases closer to neutral potential.
Table 6. The effect of in vitro opsonisation test on the size and zeta-potential of various lbl-particles.
Size change (in nanometres) shows the increase of particle diameter during the plasma incubation.??-
change (mV) is the change in zeta-potential of the particles. Opsonisation test was not performed
with all types of sodium chloride particles.
Particle       Size change (AcOH) ?-change (AcOH)     Size change (NaCl) ?-change (NaCl)
UnTHCPSi                         118,8 nm             4,8 mV        -                  -
Lbl 5 chi/alg                     140,1 nm             5,6 mV        -                  -
Lbl 5 chi/alg cl                 178,0 nm             4,4 mV        -                  -
Lbl 6 chi/alg                    226,1 nm             4,0 mV -189,8 nm         16,2 mV
Lbl 6 chi/alg cl                 185,1 nm             2,3 mV   -94,4 nm           4,7 mV
Lbl 5 chi/hepa                  221,0 nm             0,8 mV -                  -
Lbl 5 chi/hepa cl              154,1 nm             2,4 mV -                  -
Lbl 6 chi/hepa                  269,5 nm             4,8 mV   -20,3 nm           6,3 mV
Lbl 6 chi/hepa cl              143,1 nm             3,1 mV   213,2 nm           0,2 mV
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  14.1.1 SDS-PAGE
The opsonins bound to the nanoparticles were characterized with SDS-PAGE. The previous
studies  by  Rytkönen  et  al  (2011)  and  Deng  et  al  (2011)  showed  that  the  most  common
opsonins to bind to the surface of the particles are human serum albumin; size 69 kDa (HSA)
fibrinogen chains ?, ? and ?; size 49-70 kDa, and immunoglobulin G; 36 kDa (IgG). The gel
electrophoresis results with layer by layer-particles (figure 9.) support this data. The size of
the most visible protein bands (50-75 kDa) correlates with the size of these proteins even
though there are no apparent 36 kDa bands in the IgG -region.
The SDS-PAGE gels show that less plasma proteins are bound to the surface of the lbl-
particles compared to untreated particles, indicating some protection against the opsonins.
Within LbL particles there are no significant differences; five and six layered particles gave
similar results. Lbl-formation seemed to work better with alginate than with heparin as a last
layer according to visual comparison. Crosslinking had no effect on opsonisation.
Figure 9. Two SDS-PAGE-gels with similar six layered lbl-UnTHCPSi-particles. Molecular weight
marker on the left. The arrows point the protein bands of the most common opsonins in the blood
stream, fibrinogen (F) human serum albumin (H). Fibrinogen ?-chain can also be found in the
albumin region. Both gels have the same sample order, from left to right: 1 = Molecular marker, 2 =
Lbl 6 chi/alg, 3 = Lbl 6 chi/alg crosslinked, 4 = Empty, 5 = lbl 6 chi/hepa, 6 = Lbl 6 chi/hepa crosslinked,
7 = Untreated UnTHCPSi, 8 = Human plasma 1:200
1      2       3     4     5      6      7     8     1      2     3  4     5     6      7      8
H (F)
F
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  14.2 In vivo
The biodistribution of the lbl-UnTHCPSi-nanoparticles was studied with healthy mice.
PEGylated particles were chosen as a control according to the earlier studies by Rytkönen et
al  (2011).  They  showed  that  the  PEGylated  particles  accumulated  mainly  to  the  liver  and
spleen.
The possible prolonged circulation time of LbL particles were compared to PEGylated
particles. Radiolabeled particles were injected into mice via tail vein. After injection, the
mice  were  sacrificed  at  two  time  points  of  10  or  30  minutes.  The  biodistribution  was
calculated as percentage of injected dose per weight of the tissue sample.
The  blood  levels  of  the  all  five  particles  were  from  3  to  4  %  after  30  minutes  (Figure  10.)
suggesting either deiodisation or that minor part of the particles are circulating. The overall
biodistribution results (figure 11.) respectively show that lbl-particles are accumulated after
10 minutes mainly to the lungs, liver and spleen. The highest accumulation to the lungs were
found with five layered particles, which had positive charged chitosan as top layer, and was
around 20% with both crosslinked and non-crosslinked particles after 30 minutes. The lowest
accumulation was seen with PEGylated particles.
Figure 10. The blood ID%/g values of five different shielded nanoparticles.
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C5    = UnTHCPSi lbl 5 chi/alg
C5cl = UnTHCPSi lbl 5 chi/alg cl
C6    = UnTHCPSi lbl 6 chi/alg
C6cl = UnTHCPSi lbl 6 chi/alg cl
Peg = UnTHCPSi + Peg (10 kDa)
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Figure 11. The biodistribution results of the lbl-UnTHCPSi-particles, shielded with chitosan (chi) and
alginate (alg), and PEGylated particles as a control. % ID/g shows the percentage of injected dose per
weight of the tissue sample.
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DISCUSSION
The experimental section of this Master’s Thesis studied the layer-by-layer (LbL) assembly of
polysaccharides on mesoporous nanoparticles and the effect of LbL to the opsonisation and
biodistribution in mice. Both electrostatic and chemical crosslinking methods were used. The
process was monitored by light scattering methods and biodistribution with radiolabeled
particles. The aim of the study was to prevent opsonisation and increase the circulation time
of the nanoparticles.
15. Layer by layer coating
The  size  of  both  UnTHCPSi-  and  TCPSi-NH2-nanoparticles increases linearly when adding
polysaccharide layers, suggesting that the lbl-assembly may be successful. Chitosan layers
always increased the average particle size. However, adding negatively charged layers, the
size tends to increase less, sometimes it even decreased. This was seen both with alginate
and heparin, which gave very similar results.  One explanation is that particles with chitosan
as the outermost layer tend to aggregate leading to larger particle sizes while adding
negatively charged polysaccharide prevents aggregation. There was slightly lower increase in
the particle size when adding heparin layers compared to alginate probably due to heparin’s
lower molecular weight.
The zeta-potential results were unexpected. Positively charged chitosan should remarkably
increase the ?-potential while respectively negative polysaccharides should decrease it.
However, the? ?-potential stayed roughly at -20 mV with only minor variation between the
positive and the negative layers, not corresponding to the expected potential. This is not
likely due to unsuccessful lbl assembly since the size of the particles increases linearly when
adding layers. A more probable reason, which is also suggested in an earlier study by Zhou et
al. (2010), is that the polysaccharide layers cover the particles only partially, and the ?-
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potentials of the lower layers and especially the particle itself affect the measurements. It is
also possible that various molecules such as water, acetate and phthalates may be
entrapped within the polysaccharide layers or adsorbed to the silicon structure of the
particle, leading to illogical zeta-potential values.
The overall decrease of the zeta-potential with TCPSi-NH2-particles cannot be explained by
the partial polymer shield as their potential dropped to -20 mV regardless of the highly
positive particle charge. Again, the entrapped molecules might have some influence but it
seems that acetate buffer as washing solution is the main cause for the illogical ?-potentials
and may interfere both size and zeta-potential of the lbl-particles. Probably, acetate groups
with negative charge interact with the surface structure of the nanoparticles and the
polysaccharide layers, thus keeping the ?-potential negative. Nevertheless, to confirm the
exact mechanism, more experiments are needed. Sodium chloride is used to measure more
consistent ?-potentials but it is limited due to the high aggregation of the particles, which
affects the behaviour in both in vitro and in vivo experiments. Furthermore, polysaccharide
layers made in NaCl seem to be less stable. Therefore acetate buffer is the better choice of
the two regardless of the variance in ?-potentials since the size measurements showed that
the lbl formation is successful and stable.
To improve the lbl assembly, each composed layer should be denser. In the other words,
more polysaccharide units should be attached to create a stronger complete shield around
the particle. In order to achieve this, washing solution and protocol of composing each layer
should be optimized by i.e. changing incubation and sonication times. However, the
concentration of polysaccharides in ratio to the amount of nanoparticles seems to be the
most important factor. Changing the polysaccharide-nanoparticle ratio by using more
consentrated polysaccharide solution or by decreasing the amount of nanoparticles may
improve the results, since layers tended to form better when the
nanoparticle/polysaccharide ratio is low. In any case, more experimental data is needed.
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16. Opsonisation
There are several studies showing that the layer-by-layer assembly decreases opsonisation.
In this study during the incubation in human plasma, the size of the lbl-particles tend to
increase more than that of the untreated particles, suggesting  that there are more opsonins
bound to the surface of the lbl-particles. However, aggregation caused by plasma, may give
false results since dynamic light scattering measurements have shown that the particles with
multiple polysaccharide layers aggregated more easily than the particles with few or no
layers at all. Therefore the actual size of the opsonin corona around the particles remains
unclear.
The change in zeta-potential after the plasma test is always slightly positive, which is logical
as most of the opsonins are negatively charged, but the charge is not as low as the ?-
potential of the lbl-particles before the incubation in plasma. Therefore, the bound opsonins
increase the charge of the particles. Nonetheless, the positive change in? ?-potential is low
and there are no major differences between the various lbl-particles and the untreated ones,
which leads to the conclusion that the changes in particle size and ?-potential do not directly
indicate whether lbl-assembly decreases opsonisation or not.
The results from SDS-PAGE-gels were promising. Six layered UnTHCPSi-particles made using
sodium chloride as washing solution showed lowest opsonisation degree. The intensity of
the protein bands of the most common opsonins, fibrinogen and human serum albumin, was
weaker with the lbl-particles compared to the control. This suggests that the lbl-assembly
may prevent opsonisation at some level, since less opsonin was monitored. The minor
differences between the lbl-assemblies of chi/alg and chi/hepa may be due to the size of the
polysaccharides;  heparin  (5-30  kDa)  is  considerably  shorter  than  alginate  (80-120  kDa).
Therefore heparin may not cover the particle as comprehensively as alginate.
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17. Radiolabelling and biodistribution
Radiolabelling with UnTHCPSi-particles conjugated with tyrosine was shown to work well.
Radiolabeling efficiency of the tyrosinated particles was high enough for the biodistribution
studies. Furthermore, the nanoparticles labelled with iodine were stable in human plasma.
Surprisingly, radiolabeling efficiency with TCPSi-NH2-particles was highest with the original
primary amino derivated nanoparticles, while phloretic acid or polysaccharide layers
decreased the labelling efficiency. This suggests that the radioactive iodine tends to adsorb
directly to the mesoporous silicon structure of the particles instead of their surface
structure, but the mechanism of the reaction is unclear. The molecules conjugated on the
surface of the nanoparticles, may partially block the iodine binding to the silicon structure,
which explains the decrease in labelling efficiency. The labelling efficiency was clearly lower
with  UnTHCPSi  than  with  TCPSi-NH2-particles but the variation was not seen in their same
scale with the UnTHCPSi-particles even though they have similar mesoporous silicon
structure. It seems that the differences in the surface structure cause the considerably lower
radiolabeling efficiency of the UnTHCPSis. The number of undecylenic acid groups on the
surface  of  the  UnTHCPSis  may  be  lower  than  the  number  of  the  amino  structures  on  the
surface TCPSi-NH2-particles.
Although the stability tests in plasma showed that the radiolabel is relative tightly bound to
the particles, the stability in vivo remains open since the exact structural position of the
iodine in the nanoparticle is not known. In order to prevent direct labelling, radioactive
iodine should be bound to phloretic acid before it is conjugated to the amino particles. A
disadvantage of this is that the particles should be radiolabelled before any surface
modifications like lbl-assembly, since altered surface structure has effect on phloretic acid
conjugation.
Biodistribution was studied with UnTHCPSi-particles only. PEGylated particles were chosen
as  a  control  since  the  previous  study  by  Rytkönen  et  al  (2011)  showed  that  there  are  no
significant differences in biodistribution between the PEGylated UnTHCPSi-particles and the
untreated ones. As predicted, the results show that all particle modifications were rapidly
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removed from the blood stream. Opsonins of the circulation attached onto the surface of
the particles regardless of the shielding layers, crosslinking or PEG-molecules, leading to
macrophage uptake and accumulation to the organs of the mononuclear phagocyte system,
mainly liver and spleen. This indicates that the layer by layer assembly doesn’t remarkably
decrease the opsonisation level and thus increase the circulation time. The shielding layers
may not provide complete cover around the particles and therefore increasing the
polysaccharide layers may improve the biodistribution results.
There is however one noteworthy difference in the behaviour of the different lbl-particles.
During the first ten minutes after the injection particles with five polysaccharide layers tend
to accumulate in the lungs, from where they then are removed by the alveolar macrophages
and carried to liver and spleen. Probably, positive charged chitosan as the outermost layer
may be a partial cause since the six layered particles with negative charged alginate as the
outermost layer accumulated considerably less in the lungs. Also, aggregation and particle
size have impact on the lung accumulation as suggested in earlier studies by He et al (2011)
and Liu et al (2009). This behaviour of the particles may be used when designing lung specific
drug carriers. If the accumulation time and rate of the five layered particles could be
decreased for example by improving the coverage of the outermost chitosan layer, and the
release profile of loaded drug molecule is suitable, the particles may be used to successfully
deliver drugs to the lungs. At any case, more in vitro and in vivo experiments are needed to
confirm these results.
18. The effect of crosslinking
There was no direct proof of the successful crosslinking of the polysaccharide layers but the
crosslinking clearly changes some characteristics of the particles. The average size of both
UnTHCPSi- and TCPSi-NH2-particles layered in acetate buffer increased compared to the
corresponding non-crosslinked particles. In saline particles tended to aggregate but size of
the crosslinked sodium chloride particles on the other hand decreased slightly. Crosslinking
may decrease the level of aggregation of the already highly aggregated particles. These
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changes indicate that there are some structural modifications of the polysaccharide layers
caused by crosslinking.
There are also some structural changes in the sodium chloride lbl-particles (chi/alg) since
their zeta-potential changes considerably, from -41,5 mV to -27,4 mV, as a result of
crosslinking. This is explained by the decrease of carboxylic acid groups of the outermost
alginate layer, which are the reason for the negative charge of alginate. Crosslinking forms
amide bonds between these carboxyls and the amine groups of chitosan layers, thus
decreasing the negative ?-potential.
The measurements after the incubation in plasma showed that the size of the crosslinked
particles increased less than non-crosslinked except with LbL 5 chi/alg particles, where
chitosan is the outermost layer.  Although the size change was lowest with untreated
particles, the relative intensity of the protein bands in SDS-PAGE gel was clearly lower with
crosslinked particles than with untreated ones suggesting further that LbL particles
aggregate in plasma.
Crosslinking didn’t remarkably affect to the radiolabeling efficiency of the different lbl-
particles. There is a minor decrease in efficiency with UnTHCPSi-particles, but respectively an
increase with TCPSi-NH2 –particles. The changes are small and insignificant, but may support
the conclusion that the crosslinking causes structural changes to the polysaccharide layers
and thus alters the characteristics and behaviour of the particles.
Biodistribution of the crosslinked lbl-particles didn’t differ much from that of the non-cross
linked lbl-particles. The accumulation of the particles in lung during the first 10 minutes after
injection is slightly lower with the crosslinked particles. However, the difference is significalt
only with LbL 5 particles.
The polysaccharide layers can be crosslinked but there is no remarkable effect on the
behaviour of the lbl-particles in in vitro and in vivo experiments. Probably, the
polysaccharide layers are only partially crosslinked. To improve the crosslinking results, the
the coverage of the shielding layers should be improved, but also the crosslinking technique
could be improved for example by using heat, different crosslinking compounds such as
calcium chloride or iron solution, or by altering the reaction time.
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19. Concluding remarks
Layer-by-layer formation of polysaccharides is a versatile and promising method of
preventing opsonisation. However, the results of this study don’t directly show that LbL
layering method is working with mesoporous silicon nanoparticles. The most important
issues to resolve are to receive logical zeta-potential values and to improve the
bioavailability via modulation of the density of the polysaccharide layers which may further
decrease the opsonisation. This may be achieved by increasing the number of the layers and
also improving the crosslinking chemistry. Furthermore, in addition of shielding properties,
lbl-assembly as a method to facilitate the development of target specific drug carriers should
be studied more specifically.
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